GSK269962AROCK inhibitor CAS# 850664-21-0 |
2D Structure
- PF-04691502
Catalog No.:BCC3837
CAS No.:1013101-36-4
- NVP-BGT226
Catalog No.:BCC3827
CAS No.:1245537-68-1
- HS-173
Catalog No.:BCC5363
CAS No.:1276110-06-5
- CUDC-907
Catalog No.:BCC2154
CAS No.:1339928-25-4
- PIK-93
Catalog No.:BCC2519
CAS No.:593960-11-3
- XL147
Catalog No.:BCC2487
CAS No.:956958-53-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 850664-21-0 | SDF | Download SDF |
PubChem ID | 16095342 | Appearance | Powder |
Formula | C29H30N8O5 | M.Wt | 570.6 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | GSK 269962 | ||
Solubility | DMSO : ≥ 30 mg/mL (52.58 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide | ||
SMILES | CCN1C2=CC(=NC=C2N=C1C3=NON=C3N)OC4=CC=CC(=C4)NC(=O)C5=CC=C(C=C5)OCCN6CCOCC6 | ||
Standard InChIKey | YOVNFNXUCOWYSG-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C29H30N8O5/c1-2-37-24-17-25(31-18-23(24)33-28(37)26-27(30)35-42-34-26)41-22-5-3-4-20(16-22)32-29(38)19-6-8-21(9-7-19)40-15-12-36-10-13-39-14-11-36/h3-9,16-18H,2,10-15H2,1H3,(H2,30,35)(H,32,38) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent Rho kinase (ROCK) inhibitor (IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively). Displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. Induces vasorelaxation in preconstricted rat aorta (IC50 = 35 nM); lowers blood pressure in a rat model of hypertension. |
GSK269962A Dilution Calculator
GSK269962A Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7525 mL | 8.7627 mL | 17.5254 mL | 35.0508 mL | 43.8135 mL |
5 mM | 0.3505 mL | 1.7525 mL | 3.5051 mL | 7.0102 mL | 8.7627 mL |
10 mM | 0.1753 mL | 0.8763 mL | 1.7525 mL | 3.5051 mL | 4.3814 mL |
50 mM | 0.0351 mL | 0.1753 mL | 0.3505 mL | 0.701 mL | 0.8763 mL |
100 mM | 0.0175 mL | 0.0876 mL | 0.1753 mL | 0.3505 mL | 0.4381 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GSK269962A(GSK269962) is a potent ROCK inhibitor (IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively); displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases.
- Alogliptin Benzoate
Catalog No.:BCC1341
CAS No.:850649-62-6
- Alogliptin (SYR-322)
Catalog No.:BCC2113
CAS No.:850649-61-5
- Apigenin 5-O-neohesperidoside
Catalog No.:BCN6840
CAS No.:850630-40-9
- Norviburtinal
Catalog No.:BCN4399
CAS No.:85051-41-8
- Fmoc-Arg(Tos)-ol
Catalog No.:BCC2588
CAS No.:850330-29-9
- Rosin
Catalog No.:BCN5969
CAS No.:85026-55-7
- Cinchonain IIb
Catalog No.:BCN7738
CAS No.:85022-68-0
- Shikonofuran A
Catalog No.:BCN2826
CAS No.:85022-66-8
- ADL5859 HCl
Catalog No.:BCC1265
CAS No.:850173-95-4
- Afatinib dimaleate
Catalog No.:BCC1330
CAS No.:850140-73-7
- Sulfatinib
Catalog No.:BCC8811
CAS No.:1308672-74-3
- 5-Methoxysuberenone
Catalog No.:BCN3638
CAS No.:85011-58-1
- BX517(PDK1 inhibitor2)
Catalog No.:BCC6391
CAS No.:850717-64-5
- NBI-98782
Catalog No.:BCC4277
CAS No.:85081-18-1
- Cinchonain IIa
Catalog No.:BCN7716
CAS No.:85081-23-8
- Danoprevir (RG7227)
Catalog No.:BCC2106
CAS No.:850876-88-9
- Amuvatinib (MP-470, HPK 56)
Catalog No.:BCC2258
CAS No.:850879-09-3
- THIP hydrochloride
Catalog No.:BCC6803
CAS No.:85118-33-8
- 2-Methoxystypandrone
Catalog No.:BCN4400
CAS No.:85122-21-0
- PF9 tetrasodium salt
Catalog No.:BCC7854
CAS No.:851265-78-6
- Phospho-Glycogen Synthase Peptide-2 (substrate)
Catalog No.:BCC5747
CAS No.:851366-97-7
- (S)-4-Carboxy-3-hydroxyphenylglycine
Catalog No.:BCC6600
CAS No.:85148-82-9
- Curculigoside C
Catalog No.:BCN3696
CAS No.:851713-74-1
- OC000459
Catalog No.:BCC4507
CAS No.:851723-84-7, 950688-14-9 (sodium salt)
Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.[Pubmed:25728708]
Pigment Cell Melanoma Res. 2015 May;28(3):307-17.
No effective targeted therapy is currently available for NRAS mutant melanoma. Experimental MEK inhibition is rather toxic and has only limited efficacy in clinical trials. At least in part, this is caused by the emergence of drug resistance, which is commonly seen for single agent treatment and shortens clinical responses. Therefore, there is a dire need to identify effective companion drug targets for NRAS mutant melanoma. Here, we show that at concentrations where single drugs had little effect, ROCK inhibitors GSK269962A or Fasudil, in combination with either MEK inhibitor GSK1120212 (Trametinib) or ERK inhibitor SCH772984 cooperatively caused proliferation inhibition and cell death in vitro. Simultaneous inhibition of MEK and ROCK caused induction of BimEL , PARP, and Puma, and hence apoptosis. In vivo, MEK and ROCK inhibition suppressed growth of established tumors. Our findings warrant clinical investigation of the effectiveness of combinatorial targeting of MAPK/ERK and ROCK in NRAS mutant melanoma.
Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.[Pubmed:17018693]
J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
Increased Rho kinase (ROCK) activity contributes to smooth muscle contraction and regulates blood pressure homeostasis. We hypothesized that potent and selective ROCK inhibitors with novel structural motifs would help elucidate the functional role of ROCK and further explore the therapeutic potential of ROCK inhibition for hypertension. In this article, we characterized two aminofurazan-based inhibitors, GSK269962A [N-(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4, 5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]-oxy}benzamide] and SB-7720770-B [4-(7-{[(3S)-3-amino-1-pyrrolidinyl]carbonyl}-1-ethyl-1H-imidazo[4,5-c]pyridin-2- yl)-1,2,5-oxadiazol-3-amine], as members of a novel class of compounds that potently inhibit ROCK enzymatic activity. GSK269962A and SB-772077-B have IC50 values of 1.6 and 5.6 nM toward recombinant human ROCK1, respectively. GSK269962A also exhibited more than 30-fold selectivity against a panel of serine/threonine kinases. In lipopolysaccharide-stimulated monocytes, these inhibitors blocked the generation of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-alpha. Furthermore, both SB-772077-B and GSK269962A induced vasorelaxation in preconstricted rat aorta with an IC50 of 39 and 35 nM, respectively. Oral administration of either GSK269962A or SB-772077-B produced a profound dose-dependent reduction of systemic blood pressure in spontaneously hypertensive rats. At doses of 1, 3, and 30 mg/kg, both compounds induced a reduction in blood pressure of approximately 10, 20, and 50 mm Hg. In addition, administration of SB-772077-B also dramatically lowered blood pressure in DOCA salt-induced hypertensive rats. SB-772077-B and GSK269962A represent a novel class of ROCK inhibitors that have profound effects in the vasculature and may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases.
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.[Pubmed:17201404]
J Med Chem. 2007 Jan 11;50(1):2-5.
The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented. Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases. Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension.